Abstract: Methods are described for treating an influenza viral infection or associated diseases, disorders or mechanisms in a subject, comprising administering to the subject a therapeutically effective amount of a catecholic butane of the general formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represents a hydrogen, a lower alkyl, a lower acyl, an alkylene, or —OR1 and —OR2 each independently represents an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof; R3, R4, R5, R6, R10, R11, R12 and R13 each independently represents a hydrogen, or a lower alkyl; and R7, R8 and R9 each independently represents a hydrogen, —OH, a lower alkoxy, a lower acyloxy, an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof, or any two adjacent groups together may be an alkyene dioxy; with the proviso in certain circumstances that where one of R7, R8 and R9 represents a hydrogen, then —OR1, —OR2 and the oth

Abstract: A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of macromolecular assemblies.

Abstract: Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies.

Abstract: Described herein are compositions and methods related to wound treatment. Compositions are multi-components admixed in amounts and ratios to meet specific objectives for optimally treating various types of wound injury.

Abstract: A dispensing device having a polymer which is combined with a therapeutic agent in the form of a microparticle which is compressed to form a controlled release dispensing device and methods of locally administering a therapeutic agent using said microparticles.

Abstract: A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length of from about 0.1 to about 12 mm and can be of varying diameters and each unit dose provides a release of therapeutically active agents over at least about 8 hours. Methods of preparing the unit doses as well as extrusion processes and methods of treatment are also disclosed.

Abstract: A therapeutic compound consisting of human telomerase, its catalytic subunit hTert, or a known variant of either, and a biodegradable nanoparticle carrier, which can be administered to cells in a cell culture or in a living animal, is provided herein. The therapeutic compound is envisioned as a method for treating a wide variety of age-related diseases such as idiopathic pulmonary fibrosis, aplastic anemia, dyskeratosis congenita, arteriosclerosis, macular degeneration, osteoporosis, Alzheimer's, diabetes type 2, and any disease that correlates with telomere shortening and may be corrected or ameliorated by lengthening telomeres. The therapeutic compound is also envisioned as method for potentially treating more generic problems of human aging.

Abstract: The present invention relates to nanoparticles comprising a platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor, especially a PDGF receptor tyrosine kinase inhibitor having a water-solubility at 20° C. between about 2.

Abstract: Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed.

Abstract: The present invention provides a sustained release microsphere composition comprising (i) microspheres comprising (A) a biodegradable polymer which is a homopolymer of lactic acid or a copolymer of lactic acid and glycolic acid having a monomer ratio in the range of about 1:1 to about 3:1, and (B) a therapeutically effective amount of goserelin or a pharmaceutically acceptable salt thereof, and (ii) pharmaceutically acceptable excipients, which when injected intramuscularly, delivers goserelin or a pharmaceutically acceptable salt thereof, for a period of at least one month.

Abstract: The invention relates to spherical particles formed by polymer chains containing approximately from 30 to 10000 monomer units derived from monocyclic polycyclic alkene polymerization, wherein at least one monomer unit is substituted by an R chain including ethylene polyoxide which is optionally covalently linked to the polymer units through a hydrolyzable bridge and substituted by a reactive function, optionally engaged in a link with an active principle or a biological molecule such as protein, wherein the chain R is covalently linked to the monomer units. The use of the inventive spherical particles for preparing pharmaceutical and cosmetic compositions or surface coatings is also disclosed.

Abstract: Polymeric microcarriers suitable for use in cell culture processes and the methods of making such polymeric microcarriers by emulsion/aggregation polymerization processes.

Abstract: According to an aspect of the invention, injectable polymeric particles are provided that contain a copolymer that contains a hydroxy-acid-based repeat unit selected from a mono(hydroxy acid) unit and a poly(hydroxy acid) unit, an alkyl-ether-based repeat unit selected from a mono(alkyl ether) unit and a poly(alkyl ether) unit, and an acid-based repeat unit selected from a unit comprising multiple carboxylic acid groups and a derivative thereof Other aspects of the invention pertain to methods of making such particles. Still other aspects of the invention pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions.

Abstract: In accordance with one aspect of the invention, implantable medical devices are provided which include polymeric compositions that comprise at least one type of biodegradable ionic polymer. The at least one type of biodegradable ionic polymer comprises a biodegradable polymer core and one or more ionic end groups.

Abstract: The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering to a mammal an injectable suspension containing the polyvinylalcohol microspheres and a suitable liquid carrier. Finally, the present invention relates to a process for producing the polyvinylalcohol microspheres.

Abstract: A sustained release microsphere composition comprising— (i) microspheres comprising (A) a biodegradable polymer which is a homopolymer of lactic acid or a copolymer of lactic acid and glycolic acid having a monomer ratio in the range of about 1:1 to about 3:1, and (B) a therapeutically effective amount of octreotide acetate, and (ii) pharmaceutically acceptable excipients, which when injected, delivers octreotide acetate, for a period of at least one month.

Abstract: Bioresorbable compositions for treating skeletal tissue are disclosed. The biomedical compositions are formed from a polylactide polymer, a polyglycolide polymer, or a poly(lactic-co-glycolic acid) polymer having a relatively low molecular weight. For instance, the average number molecular weight of the polymer is generally less than 10,000, such as from about 500 to about 5,000. Fumarate groups are incorporated into the low molecular weight polymer that provide crosslinking sites. If desired, ethylene oxide groups and ceramic particles may also be incorporated into the polymer for producing compositions having a variety of properties. For example, the biomedical composition of the present disclosure can be used to treat soft skeletal tissue or to treat hard skeletal tissue. The biomedical compositions are biodegradable and can contain various therapeutic, beneficial and pharmaceutical agents that may be released during degradation of the polymer.

Abstract: The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer surface of the magnetic metal oxide. Pharmaceutical compositions comprising these nanoparticles may be used, inter alia, for detection and treatment of tumors and inflammations.

Abstract: One aspect is a method for improved preparation of molecular imprinted polymer (MIP) particles, where initial compositions comprising insoluble MIP particles are enriched for those MIP particles that bind a particular target molecule, thus excluding non-binding and weakly binding particles from the final composition. Enrichment is typically accomplished via use of chromatographic methods capable of separating particulate material or by means of agglutination. Another aspect is preparation of improved insoluble MIPs by use of extended micronization of raw MIP particles with a view to expose a large number of binding sites per mass unit of MIP particles. In preferred embodiments the two aspects are combined. The resulting improved MIPs may be used for diagnostic, analytical and therapeutic purposes, notably as orally administered drugs which can bind substances such as cholesterol and bile acids and bile acid salts in the gastrointestinal tract.

Abstract: Provided herein is a poly(ester amide) (PEA) polymer blend and a polymeric coating containing the PEA polymer blend. The PEA polymer blend has a Tg above the Tg of poly(ester amide benzyl ester) (PEA-Bz) or the Tg of poly(ester amide TEMPO). The PEA polymer blend can form a coating on an implantable device, one example of which is a stent. The coating can optionally include a biobeneficial material and/or optionally with a bioactive agent. The implantable device can be used to treat or prevent a disorder such as one of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

Abstract: Cross-linked polymer particles, as well as related compositions and methods, are disclosed.

Abstract: In accordance with one aspect of the invention, novel compositions containing injectable particles are provided in which the injectable particles contain at least two polymeric components that differ in composition from one another (e.g., because at least one polymeric component contains a polymer that is not present in another polymeric component).

Abstract: The compositions described herein include a first polymer that is either a polyvinyl alcohol or a polyvinyl formal, and a second polymer that is one of a polyvinyl alcohol, a polyvinyl formal, polyvinylpyrrolidone, a polysaccharide, or a polymethacrylate. The first polymer and the second polymer in the composition are different. These compositions are useful in the formation of particles, such as embolic particles, or other medical devices. The compositions are also useful in the delivery of therapeutic agents. Different ratios of the first polymer to the second polymer can provide different rates of release of the therapeutic agent from the composition.

Abstract: The present invention provides sustained release dosage forms comprising Paliperidone and processes for preparing the same.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: Orally deliverable pharmaceutical compositions are provided comprising a drug of tow water solubility suspended in an aqueous liquid vehicle comprising a wetting agent, a thixotropic thickening agent, and an inorganic suspending agent. The compositions are thixotropic, substantially deflocculated, and substantially physically stable.

Abstract: Provided herein is a bioabsorbable implantable device comprising a bioactive agent and a poly(ester amide) (PEA) polymer blend.

Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Abstract: The invention relates to controlled release formulations comprising a microparticle comprising a biodegradable polymer and one or more interferon compounds and methods of using the formulations.

Abstract: The present disclosure is directed generally to lanthanide nanoparticle conjugates, such as gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, conjugation to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.

Abstract: The invention is intended for a treatment of severe infections using an injectable drug-delivery system comprising nanoparticles of a biodegradable polymer with incorporated antibacterial drug.

Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Abstract: Described herein are compositions comprising particles of poorly soluble drugs encapsulated by stabilizers. Further described are pharmaceutical compositions comprising such encapsulated compositions. Also described are methods of making such encapsulated particle compositions, and methods of making the corresponding pharmaceutical compositions. The encapsulated particle compositions described herein allow poorly soluble drugs to be administered with good bioavailability by routes that are non-invasive to patients, such as by oral administration.

Abstract: A process for the preparation of polymeric nanoparticles, in which an emulsion of monomers and additional components is produced in a nonsolvent and subsequently illuminated, makes it possible to prepare polymeric nanoparticles which comprise, in a desired concentration, an effect substance, for example a dye, and/or an active substance, for example a herbicide.

Abstract: Methods of making polymer particles, as well as related particles, compositions, and methods are disclosed.

Abstract: Anti-angiogenic peptides that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR). Such peptides may also be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases and skin disorders.

Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.

Abstract: The invention relates to an improved method for administering live cells to a patient and compositions useful in the method. The composition comprises live cells and biocompatible, biodegradable polymer microparticles. The cells and microparticles of the cell/microparticle composition can be contacted immediately prior to administration, or can be contacted in culture for a specified period of time prior to administration. In the method of the invention, an effective amount of the cell/microparticle composition is administered to a patient in need thereof by injection to a treatment site of the patient to provide a therapeutic effect in the patient. The therapeutic effect can be, for example, the formation of new tissue at the treatment site, or the production and secretion of a biologically active secretory molecule at the treatment site. The therapeutic effect resulting from injection of the cell/microparticle composition into a treatment site, is determined by the type of cell present in the composition.

Abstract: Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

Abstract: Electrospray systems and modified electrospray systems for the fabrication of core-shell particles for controlled-release and/or sustained-release treatment and delivery are herein disclosed. The electrospray system may include between one and a plurality of co-axially situated tubes. Each tube may be electrically connected to a power supply wherein a voltage may be applied thereto. Core-shell particles may be collected on a collection target, which may be a wet or dry collector, and electrically connected to the power supply. Core-shell particles and methods of manufacture are also disclosed. The precursors of the core-shell particles may be polymer- or biomacromolecule-based solutions and may include at least one treatment agent incorporated therein. The number of “core” particle(s) within the “shell” may vary and may provide different treatment agent release profiles depending on the material and/or chemical characteristics of the polymer and/or biomacromolecule used.

Abstract: The invention relates to loaded microspheres with a mean diameter of 0.001 to 1 mm, and loaded with one or more absorbed or adsorbed active principles, which are obtained by mixing fine-particle polymethyl methacrylate or methyl methacrylate cross polymer with lipophilic or hydrophilic active principles until they have been absorbed or adsorbed by the surface of the polymer and a dry powder, granules or a paste is obtained. When applied to textile or fiber finishing, the loaded microspheres provide extended release of active cosmetic or pharmaceutical active principles.

Abstract: The invention pertains to biomaterial compositions and implantable systems for application to a tissue site in a living mammalian body. The compositions and systems react with tissue surfaces and components present in physiological fluids at the region of implantation, obviating the need to remove such fluids and improving the adhesion and resorption rate of the resulting bioimplant. Delivery devices and methods of use are also provided.

Abstract: The present invention relates to novel particles comprising polyelectrolyte polymers which are transporters of active principle (AP), in particular protein and peptide active principle, and to novel modified-release pharmaceutical formulations comprising said AP microparticles. These novel particles loaded with AP release the AP over a prolonged period of time of several days, or even several weeks.

Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.

Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Abstract: The present invention is a method of using compacted nucleic acid (such as DNA) nanoparticles for non-viral gene transfer to various tissues of the human eye or eyes of other mammals. These nanoparticles comprise, in one embodiment, a neutrally-charged complex containing a single molecule of plasmid DNA compacted with polyethylene glycol (PEG)-substituted poly lysine peptides.

Abstract: The present invention provides spray-dried polyene compositions for oral inhalation to the lung. The polyene antifungal compositions demonstrate superior aerosol properties, do not exhibit appreciable degradation of the polyene upon spray-drying, and are useful in the treatment and prophylaxis of both pulmonary and systemic fungal infections.

Abstract: The present invention is directed to size-stabilized drug nanoparticulate compositions and methods of preparation thereof.

Abstract: Compositions and methods of using the compositions to achieve a therapeutic effect are provided.

Abstract: A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm.